NERV — Minerva Neurosciences Share News
0.000.00%
Last trade - 00:00Minerva Neurosciences Inc expected to post a loss of $1.29 a share - Earnings Preview
Brief: Minerva Neurosciences Reports Qtrly Loss Per Share Of $1.26
Minerva Neurosciences Inc reports results for the quarter ended in December - Earnings Summary
Minerva Neurosciences Inc expected to post a loss of 92 cents a share - Earnings Preview
Minerva Neurosciences Inc expected to post a loss of 92 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Pixelworks, Gorilla Technology, CSX Corp
U.S. STOCKS ON THE MOVE-Kilroy Realty, Morgan Stanley, T2 Biosystems
U.S. STOCKS ON THE MOVE-Minerva Surgical, Jounce Therapeutics, Southwest Airlines
Minerva Neurosciences down as FDA refuses to review schizophrenia drug again
Brief: Minerva Neurosciences Announces Update On Its New Drug Application (NDA) For Roluperidone
Brief: Minerva Neurosciences Receives Notice Of Delisting From Nasdaq
Minerva Neurosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Minerva Neurosciences Reports Third Quarter Results
Minerva Neurosciences Inc expected to post a loss of $1.32 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Domino's Pizza, Juniper Networks, Walmart
U.S. STOCKS ON THE MOVE-Alvotech, Verizon, Lyft, BofA
U.S. STOCKS ON THE MOVE-Gold miners, Protera, Sorrento
Minerva Neurosciences plunges after FDA refuses to accept schizophrenia drug filing
Brief: Minerva Neurosciences Receives Refusal To File Letter From FDA For Its New Drug Application For Roluperidone